Table 3.
Efficacies of phase 4 vaccines against B.1.1.7 (Alpha) and B.1.617.2 (delta) variant reported in various demographic regions
| Sl. No. | Vaccines | Country/region | Dose | Vaccine efficacy B.1.17 (%) | Vaccine efficacy B.1.617.2 (%) | References |
|---|---|---|---|---|---|---|
| 1 | ChAdOx1 | Canada | 1 | 64 | 67 | [88] |
| 2 | BNT162b2 | 1 | 66 | 56 | ||
| BNT162b2 | 2 | 89 | 87 | |||
| 3 | mRNA-1273 | 1 | 83 | 72 | ||
| mRNA-1273 | 2 | 92 | / | |||
| 4 | ChAdOx1 | UK | 1 | 51.1 | 33.5 | [84] |
| 5 | BNT162b2 | 1 | 51.1 | 33.5 | ||
| 6 | ChAdOx1 | 2 | 86.8 | 80.6 | ||
| 7 | BNT162b2 | 2 | 93.4 | 87.9 | ||
| 8 | ChAdOx1 | Scotland | 1 | 37 | 18 | [143] |
| 9 | BNT162b2 | 1 | 38 | 30 | ||
| 10 | ChAdOx1 | 2 | 73 | 60 | ||
| 11 | BNT162b2 | 2 | 92 | 79 | ||
| 12 | BBV152 | India | 2 | 98.6 | 65.2 | [89, 90] |
INDEX:
BNT162b2: Pfizer–BioNTech COVID-19 vaccine
ChAdOx1: Oxford–AstraZeneca COVID-19 vaccine
mRNA-1273: Moderna COVID-19 vaccine
BBV152: Covaxin